Vishal Goyal

Also affiliated with Drugs for Neglected Diseases Initiative, Maharishi Markandeshwar University, Mullana, Punjab Engineering College

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial”.

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

The Lancet. Gastroenterology & hepatology(2021)10.1016/s2468-1253(21)00031-5

N/A

2.5DataRank · unranked

41 citations

Soek-Siam Tan, Sombat Thanprasertsuk, Nicolas Salvadori, Caroline Menétrey, François Simon +20 more